 Jessica Finlay-Schultz
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 16 | 2025 | 2132 | 1.730 |
Why?
| | Progestins | 5 | 2020 | 78 | 1.240 |
Why?
| | Receptors, Estrogen | 10 | 2025 | 424 | 1.160 |
Why?
| | Receptors, Progesterone | 6 | 2020 | 341 | 1.030 |
Why?
| | Progesterone | 4 | 2017 | 242 | 0.900 |
Why?
| | Neoplastic Stem Cells | 5 | 2020 | 386 | 0.870 |
Why?
| | Keratin-5 | 5 | 2022 | 49 | 0.730 |
Why?
| | Cell Line, Tumor | 12 | 2025 | 3184 | 0.730 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 48 | 0.660 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2020 | 82 | 0.660 |
Why?
| | Estrogens | 4 | 2017 | 342 | 0.630 |
Why?
| | RNA Polymerase III | 1 | 2017 | 26 | 0.560 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1351 | 0.460 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 48 | 0.460 |
Why?
| | MicroRNAs | 3 | 2015 | 677 | 0.430 |
Why?
| | Receptors, Nicotinic | 2 | 2011 | 322 | 0.390 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 313 | 0.390 |
Why?
| | Mice, SCID | 5 | 2020 | 350 | 0.380 |
Why?
| | Transcription Factor AP-2 | 1 | 2011 | 83 | 0.370 |
Why?
| | Receptor, ErbB-2 | 3 | 2020 | 325 | 0.340 |
Why?
| | Mice, Inbred NOD | 4 | 2020 | 586 | 0.330 |
Why?
| | Heterografts | 2 | 2020 | 129 | 0.300 |
Why?
| | Signal Transduction | 5 | 2021 | 4826 | 0.290 |
Why?
| | Schizophrenia | 1 | 2011 | 428 | 0.280 |
Why?
| | Receptors, Androgen | 2 | 2021 | 143 | 0.270 |
Why?
| | Tamoxifen | 4 | 2025 | 200 | 0.270 |
Why?
| | Androgens | 2 | 2021 | 173 | 0.270 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2025 | 11 | 0.240 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1688 | 0.240 |
Why?
| | Transcriptome | 3 | 2020 | 881 | 0.230 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2020 | 814 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 749 | 0.210 |
Why?
| | Mice | 10 | 2020 | 16602 | 0.200 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.200 |
Why?
| | Cell Proliferation | 6 | 2025 | 2344 | 0.200 |
Why?
| | Triglycerides | 1 | 2025 | 523 | 0.200 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2505 | 0.190 |
Why?
| | Lipid Metabolism | 1 | 2025 | 491 | 0.190 |
Why?
| | Thyroid Hormones | 1 | 2020 | 54 | 0.170 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 608 | 0.170 |
Why?
| | Estrogen Receptor alpha | 1 | 2021 | 132 | 0.160 |
Why?
| | Hormone Replacement Therapy | 1 | 2020 | 89 | 0.160 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1198 | 0.160 |
Why?
| | MCF-7 Cells | 4 | 2021 | 115 | 0.160 |
Why?
| | Hyaluronan Receptors | 3 | 2014 | 97 | 0.160 |
Why?
| | Up-Regulation | 2 | 2020 | 825 | 0.160 |
Why?
| | Female | 16 | 2025 | 68153 | 0.150 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2025 | 158 | 0.150 |
Why?
| | RNA, Messenger | 2 | 2019 | 2675 | 0.150 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1404 | 0.150 |
Why?
| | beta Catenin | 1 | 2020 | 219 | 0.150 |
Why?
| | Animals | 10 | 2020 | 34479 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 345 | 0.140 |
Why?
| | Tumor Cells, Cultured | 2 | 2017 | 930 | 0.140 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 14 | 0.140 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 51 | 0.140 |
Why?
| | Biomarkers, Tumor | 3 | 2022 | 1181 | 0.140 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 13 | 0.130 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 48 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 429 | 0.130 |
Why?
| | DNA Methylation | 2 | 2011 | 604 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 272 | 0.130 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 318 | 0.130 |
Why?
| | Humans | 20 | 2025 | 128417 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 35 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2016 | 325 | 0.110 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2011 | 101 | 0.110 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 258 | 0.110 |
Why?
| | Cisplatin | 1 | 2015 | 297 | 0.110 |
Why?
| | HeLa Cells | 2 | 2011 | 603 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Down-Regulation | 1 | 2014 | 631 | 0.100 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 66 | 0.100 |
Why?
| | Apoptosis | 2 | 2017 | 2435 | 0.090 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 358 | 0.090 |
Why?
| | Genetic Vectors | 1 | 2011 | 311 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 488 | 0.080 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 571 | 0.080 |
Why?
| | CD146 Antigen | 2 | 2020 | 41 | 0.070 |
Why?
| | Gene Knockout Techniques | 2 | 2020 | 109 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 853 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2012 | 1900 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 478 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2051 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 623 | 0.060 |
Why?
| | Vimentin | 1 | 2022 | 50 | 0.050 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2021 | 6 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2021 | 42 | 0.040 |
Why?
| | Doxorubicin | 1 | 2022 | 322 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2021 | 39 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3689 | 0.040 |
Why?
| | Adherens Junctions | 1 | 2020 | 26 | 0.040 |
Why?
| | Immunoprecipitation | 1 | 2020 | 157 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 107 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 647 | 0.040 |
Why?
| | Gene Library | 1 | 2019 | 115 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 267 | 0.040 |
Why?
| | Cadherins | 1 | 2020 | 186 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 480 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 165 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2020 | 209 | 0.040 |
Why?
| | Antigens, CD | 1 | 2020 | 482 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 659 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2016 | 66 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 601 | 0.030 |
Why?
| | Tretinoin | 1 | 2017 | 128 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2016 | 187 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2016 | 78 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2016 | 128 | 0.030 |
Why?
| | Cell Membrane | 1 | 2020 | 720 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 539 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 57 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 484 | 0.030 |
Why?
| | Fibroblasts | 1 | 2020 | 935 | 0.030 |
Why?
| | Adult | 1 | 2017 | 35299 | 0.030 |
Why?
| | Software | 1 | 2019 | 608 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2755 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Cell Survival | 1 | 2015 | 1077 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 140 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2071 | 0.020 |
Why?
| | Glucose | 1 | 2016 | 982 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1664 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 283 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 158 | 0.020 |
Why?
| | Organ Specificity | 1 | 2011 | 291 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5388 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 756 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 280 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2602 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 615 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3937 | 0.020 |
Why?
| | Male | 2 | 2016 | 62857 | 0.010 |
Why?
|
|
Finlay-Schultz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|